STOCK TITAN

Anixa Biosciences Inc - ANIX STOCK NEWS

Welcome to our dedicated news page for Anixa Biosciences (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anixa Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anixa Biosciences's position in the market.

Rhea-AI Summary
Anixa Biosciences (ANIX) announced that its partner, Cleveland Clinic, has received an 'Intention to Grant' notice from the European Patent Office for the patent application titled 'Ovarian Cancer Vaccines.' The patent targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED) and is a significant development in the treatment and prevention of ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
-
Rhea-AI Summary
Anixa Biosciences, Inc. will present at the Ovarian Cancer National Conference to discuss the clinical development of its Phase 1 ovarian cancer CAR-T therapy. The conference is organized by the Ovarian Cancer Research Alliance, which has invested $100 million in research and advocated for $200 million in government funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences
-
Rhea-AI Summary
Anixa Biosciences completes treatment of first patient cohort in ovarian cancer clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Summary
Anixa Biosciences receives US patent for ovarian cancer vaccine technology, broadening protection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Anixa Biosciences establishes Cancer Business Advisory Board
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
management
-
Rhea-AI Summary
Anixa Biosciences to participate in two investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
Rhea-AI Summary
Anixa Biosciences commences treatment of third patient in clinical trial for ovarian cancer, expects to begin treatment of second cohort in Q4 2023. Therapy targets FSHR exclusively expressed on ovarian cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announces the enrollment of subjects in a treatment arm evaluating the combination of its breast cancer vaccine with Keytruda (pembrolizumab) by its partner, Cleveland Clinic. The trial aims to determine if the vaccine/Keytruda combination increases immune response against triple negative breast cancer (TNBC), with potential synergistic effects. The company looks forward to the presentation of updated data from this trial at the San Antonio Breast Cancer Symposium in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
Anixa Biosciences Inc

Nasdaq:ANIX

ANIX Rankings

ANIX Stock Data

101.12M
30.38M
4.9%
13.9%
1.81%
Computer Storage Device Manufacturing
Manufacturing
Link
US
San Jose

About ANIX

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues